Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | aldehyde dehydrogenase 1 family, member A1 | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Mycobacterium tuberculosis | Succinate-semialdehyde dehydrogenase [NADP+] dependent (SSDH) GabD1 | aldehyde dehydrogenase 1 family, member A1 | 501 aa | 456 aa | 33.3 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.2997 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.2997 | 1 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0073 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.2997 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.2997 | 0.2925 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0073 | 1 | 0.5 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Echinococcus multilocularis | musashi | 0.0033 | 0.2997 | 0.2925 |
Echinococcus multilocularis | lamin | 0.0033 | 0.2997 | 0.2925 |
Echinococcus granulosus | lamin | 0.0033 | 0.2997 | 0.2925 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0073 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0102 | 0.0342 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.2895 | 0.9658 |
Onchocerca volvulus | 0.0033 | 0.2997 | 0.5 | |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0073 | 1 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 1 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 1 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.2997 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.2997 | 0.2925 |
Onchocerca volvulus | 0.0033 | 0.2997 | 0.5 | |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0399 | 0.1333 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.2997 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.2997 | 0.2925 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.0045 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.037 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 0.0828 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 3.5481 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (binding) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 63.0957 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.